Latest from Perlmutter Cancer Center at NYU Langone

Douglas Levine, MD, discusses a recent study in uterine carcinosarcoma and early steps toward developing therapeutic regimens.
Researchers at NYU Langone Medical Center are taking an approach that focuses on the unique metabolic adaptations of pancreatic cancer.
Arjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.
Douglas A. Levine, MD, discussed the relationship between EMSY and BRCA, the potential to target EMSY amplified tumors with PARP inhibitors, and the future of ovarian cancer treatment.
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses some of the ongoing challenges researchers need to tackle in the field of ovarian cancer.
Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses combination strategies for patients with BRAF-mutant melanoma.
Theodore H. Welling, III, MD, will lead a new state-of-the-art liver cancer program at NYU Langone to advance clinical care and accelerate the translation of lab breakthroughs into superior treatments.
NYU Langone Medical Center has announced that internationally recognized surgeon and scientist Diane M. Simeone, MD, will join its Perlmutter Cancer Center on March 1 to serve as associate director for translational research and to lead its newly established pancreatic cancer center.
Publication Bottom Border
Border Publication